SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
Business Wire India Advancement to Phase 3 is major milestone for SAB’s unique DiversitAb™ immunotherapy platform that produces fully-human polyclonal antibodies without human donors Both doses of SAB-185 tested in…